<div id="readability-page-1"><p>Incyte (NASDAQ:INCY - Get Free Report) is anticipated to release its  Q4 2025 results before the market opens on Tuesday, February 10th. Analysts expect Incyte to post earnings of $1.96 per share and revenue of $1.3543 billion for the quarter. Parties are encouraged to explore the company's upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, February 10, 2026 at 8:00 AM ET.</p><h2>Incyte Trading Up 2.6%</h2><ul><li>Can Incyte Deliver on 447% EPS Forecasts and Pipeline Hype?</li></ul><p>Shares of INCY opened at $102.67 on Tuesday. The stock's 50-day moving average price is $101.82 and its 200 day moving average price is $92.31. The company has a quick ratio of 3.13, a current ratio of 3.20 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $20.16 billion, a price-to-earnings ratio of 17.20, a P/E/G ratio of 0.60 and a beta of 0.82. Incyte has a 12-month low of $53.56 and a 12-month high of $112.29. </p><h2>Insider Activity</h2><p>In other Incyte news, EVP Michael James Morrissey sold 54,008 shares of the business's stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $97.29, for a total value of $5,254,438.32. Following the transaction, the executive vice president directly owned 31,830 shares in the company, valued at $3,096,740.70. The trade was a 62.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. Also, EVP Mohamed Khairie Issa sold 10,856 shares of the company's stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $109.07, for a total transaction of $1,184,063.92. Following the sale, the executive vice president directly owned 66,132 shares in the company, valued at $7,213,017.24. This represents a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 95,225 shares of company stock valued at $9,519,745. Company insiders own  17.80% of the company's stock. </p><h2>Hedge Funds Weigh In On Incyte</h2><ul><li>5 top healthcare stocks for earnings growth in 2024</li></ul><p>Several institutional investors have recently bought and sold shares of the business. MUFG Securities EMEA plc bought a new stake in shares of  Incyte during the second quarter worth $32,000.  CYBER HORNET ETFs LLC bought a new position in shares of  Incyte in the second quarter valued at about $33,000.  CIBC Private Wealth Group LLC lifted its position in  Incyte by 153.8% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 726 shares of the biopharmaceutical company's stock worth $62,000 after buying an additional 440 shares in the last quarter.  Geneos Wealth Management Inc. grew its holdings in  Incyte by 350.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 756 shares of the biopharmaceutical company's stock worth $46,000 after acquiring an additional 588 shares during the last quarter.  Finally, Brown Brothers Harriman &amp; Co. grew its holdings in  Incyte by 43.5% during the 3rd quarter. Brown Brothers Harriman &amp; Co. now owns 818 shares of the biopharmaceutical company's stock worth $69,000 after acquiring an additional 248 shares during the last quarter. Institutional investors own  96.97% of the company's stock. </p><h2>Analyst Upgrades and Downgrades</h2><p>INCY has been the topic of a number of research reports. JPMorgan Chase &amp; Co. boosted their price objective on Incyte from $73.00 to $89.00 and gave the company a &#34;neutral&#34; rating in a research report on Thursday, October 9th. Stifel Nicolaus  set a $119.00 price target on shares of Incyte in a report on Monday, January 5th. Wells Fargo &amp; Company  reaffirmed an &#34;equal weight&#34; rating and set a $107.00 price objective (down from $116.00) on shares of Incyte in a report on Tuesday, January 20th. Zacks Research lowered shares of Incyte from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Monday, November 10th. Finally, Barclays increased their price target on shares of Incyte from $101.00 to $115.00 and gave the stock an &#34;overweight&#34; rating in a research report on Monday, November 24th. Eight equities research analysts have rated the stock with a Buy rating, twelve have issued  a Hold rating and one  has issued  a Sell rating to the company's stock. According to data from MarketBeat.com, the company  has an average rating of &#34;Hold&#34; and a consensus price target of $100.75.</p><ul><li>Argenx's 28% Surge &amp; Promising Product Propel Investor Confidence</li></ul><p><b>View Our Latest Stock Analysis on INCY</b></p><h2>Incyte Company Profile</h2> (Get Free Report)<p>Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company's research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.  </p><p>The company's flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.</p><h2>See Also</h2><ul><li>Five stocks we like better than Incyte</li><li>The day the gold market broke</li><li>Forget AI, This Will Be the Next Big Tech Breakthrough</li><li>~$1.5T SpaceX IPO: Pre-IPO Opportunity</li><li>Gold’s getting scarce.</li><li>End of America Update</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5DWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5DWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Incyte Right Now?</h2><p>Before you consider Incyte, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Incyte wasn't on the list.</p><p>While Incyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SBIO

ARKG

<p>Incyte (NASDAQ:INCY) is set to release its Q4 2025 earnings on February 10, with analysts predicting earnings of $1.96 per share and revenue of $1.3543 billion. The company's stock opened at $102.67, showing a 2.6% increase. Recent insider sales have been noted, with executives selling significant shares. Institutional investors hold 96.97% of the stock, and analysts have mixed ratings, with a consensus price target of $100.75. Incyte focuses on developing therapies in oncology and has a market cap of $20.16 billion.</p>

Incyte (INCY) to Release Earnings on Tuesday